JP2023549547A5 - - Google Patents
Info
- Publication number
- JP2023549547A5 JP2023549547A5 JP2023529022A JP2023529022A JP2023549547A5 JP 2023549547 A5 JP2023549547 A5 JP 2023549547A5 JP 2023529022 A JP2023529022 A JP 2023529022A JP 2023529022 A JP2023529022 A JP 2023529022A JP 2023549547 A5 JP2023549547 A5 JP 2023549547A5
- Authority
- JP
- Japan
- Prior art keywords
- independently
- compound
- groups
- optionally substituted
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063115552P | 2020-11-18 | 2020-11-18 | |
| US63/115,552 | 2020-11-18 | ||
| PCT/US2021/072475 WO2022109573A1 (en) | 2020-11-18 | 2021-11-17 | Macrocycles containing a 1,3,4-oxadiazole ring for use as modulators of cystic fibrosis transmembrane conductance regulator |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023549547A JP2023549547A (ja) | 2023-11-27 |
| JP2023549547A5 true JP2023549547A5 (enExample) | 2024-11-26 |
Family
ID=79602287
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023529022A Pending JP2023549547A (ja) | 2020-11-18 | 2021-11-17 | 嚢胞性線維症膜コンダクタンス制御因子のモジュレーターとして使用するための１，３，４－オキサジアゾール環を含有する大環状化合物 |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP4247817A1 (enExample) |
| JP (1) | JP2023549547A (enExample) |
| KR (1) | KR20230123522A (enExample) |
| CN (1) | CN116670140A (enExample) |
| AR (1) | AR124090A1 (enExample) |
| AU (1) | AU2021383176A1 (enExample) |
| CA (1) | CA3201793A1 (enExample) |
| CL (1) | CL2023001398A1 (enExample) |
| CO (1) | CO2023007896A2 (enExample) |
| CR (1) | CR20230260A (enExample) |
| DO (1) | DOP2023000099A (enExample) |
| EC (1) | ECSP23045439A (enExample) |
| GE (1) | GEAP202316271A (enExample) |
| IL (1) | IL302873A (enExample) |
| JO (1) | JOP20230105A1 (enExample) |
| MX (1) | MX2023005721A (enExample) |
| PE (1) | PE20231380A1 (enExample) |
| WO (1) | WO2022109573A1 (enExample) |
| ZA (1) | ZA202305296B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20230120A (es) | 2020-08-07 | 2023-09-01 | Vertex Pharma | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
| US12324802B2 (en) | 2020-11-18 | 2025-06-10 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| IL314449A (en) * | 2022-02-03 | 2024-09-01 | Vertex Pharma | Methods of treatment for cystic fibrosis |
| WO2023154291A1 (en) * | 2022-02-08 | 2023-08-17 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| EP4525858A1 (en) * | 2022-05-16 | 2025-03-26 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| CA3253977A1 (en) | 2022-05-16 | 2023-11-23 | Vertex Pharmaceuticals Incorporated | SOLID FORMS OF MACROCYCLIC COMPOUNDS AS CFTR MODULATORS AND THEIR PREPARATION |
| WO2024054851A1 (en) * | 2022-09-07 | 2024-03-14 | Sionna Therapeutics | Macrocyclic compounds, compositions and methods of using thereof |
| TW202421102A (zh) * | 2022-09-15 | 2024-06-01 | 瑞士商愛杜西亞製藥有限公司 | 巨環cftr調節劑與cftr校正子及/或cftr增效劑之組合 |
| KR20250084132A (ko) | 2022-09-15 | 2025-06-10 | 이도르시아 파마슈티컬스 리미티드 | 마크로시클릭 cftr 조절제 |
| CA3267791A1 (en) | 2022-09-15 | 2024-03-21 | Idorsia Pharmaceuticals Ltd | CRYSTALLINE FORM OF (3S,7S,10R,13R)-13-BENZYL-20-FLUORO-7-ISOBUTYL-N-(2-(3-METHOXY-1,2,4-OXADIAZOL-5-YL)ETHYL)-6,9-DIMETHYL-1,5,8,11-TETRAOXO-10-(2,2,2-TRIFLUOROETHYL)-1,2,3,4,5,6,7,8,9,10,11,12,13,14-TETRADECAHYDRO-[1]OXA[4,7,10,14]TETRAAZACYCLOHEPTADECINO [16,17-F]QUINOLINE-3-CARBOXAMIDE |
| WO2025076235A1 (en) | 2023-10-04 | 2025-04-10 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| WO2025076240A1 (en) | 2023-10-04 | 2025-04-10 | Vertex Pharmaceuticals Incorporated | Solid forms of modulators of cystic fibrosis transmembrane conductance regulator |
| WO2025186214A1 (en) | 2024-03-05 | 2025-09-12 | Idorsia Pharmaceuticals Ltd | Macrocyclic cftr modulators |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013038386A1 (en) * | 2011-09-16 | 2013-03-21 | Novartis Ag | Heterocyclic compounds for the treatment of cystic fibrosis |
| SI3519401T1 (sl) * | 2016-09-30 | 2022-01-31 | Vertex Pharmaceuticals Incorporated | Modulator regulatorja transmembranske prevodnosti pri cistični fibrozi, farmacevtski sestavki, postopki zdravljenja in proces za izdelavo modulatorja |
| CN110267948B (zh) * | 2016-12-09 | 2023-12-08 | 弗特克斯药品有限公司 | 囊性纤维化跨膜传导调控剂的调节剂、药物组合物、治疗方法和制备所述调节剂的方法 |
| TWI810243B (zh) * | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
| AU2019222758B2 (en) * | 2018-02-15 | 2022-07-07 | Vertex Pharmaceuticals Incorporated | Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cystic fibrosis, and process for making them |
| CN109134431B (zh) * | 2018-10-10 | 2021-06-04 | 成都理工大学 | 作为囊性纤维化跨膜传导调节因子抑制剂的氨基咪唑偶联吡啶酮衍生物 |
| TWI848092B (zh) * | 2019-04-03 | 2024-07-11 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白調節劑 |
-
2021
- 2021-11-17 KR KR1020237020002A patent/KR20230123522A/ko active Pending
- 2021-11-17 CA CA3201793A patent/CA3201793A1/en active Pending
- 2021-11-17 WO PCT/US2021/072475 patent/WO2022109573A1/en not_active Ceased
- 2021-11-17 AU AU2021383176A patent/AU2021383176A1/en active Pending
- 2021-11-17 EP EP21843853.9A patent/EP4247817A1/en active Pending
- 2021-11-17 GE GEAP202316271A patent/GEAP202316271A/en unknown
- 2021-11-17 PE PE2023001653A patent/PE20231380A1/es unknown
- 2021-11-17 MX MX2023005721A patent/MX2023005721A/es unknown
- 2021-11-17 CN CN202180090910.1A patent/CN116670140A/zh active Pending
- 2021-11-17 CR CR20230260A patent/CR20230260A/es unknown
- 2021-11-17 JP JP2023529022A patent/JP2023549547A/ja active Pending
- 2021-11-17 IL IL302873A patent/IL302873A/en unknown
- 2021-11-18 AR ARP210103184A patent/AR124090A1/es unknown
-
2023
- 2023-05-11 JO JOJO/P/2023/0105A patent/JOP20230105A1/ar unknown
- 2023-05-15 ZA ZA2023/05296A patent/ZA202305296B/en unknown
- 2023-05-16 CL CL2023001398A patent/CL2023001398A1/es unknown
- 2023-05-17 DO DO2023000099A patent/DOP2023000099A/es unknown
- 2023-06-16 EC ECSENADI202345439A patent/ECSP23045439A/es unknown
- 2023-06-16 CO CONC2023/0007896A patent/CO2023007896A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023549547A5 (enExample) | ||
| JP2023537484A5 (enExample) | ||
| JP2010536887A5 (enExample) | ||
| JP2023551174A5 (enExample) | ||
| JP2013530179A5 (enExample) | ||
| HRP20250694T1 (hr) | Modulatori regulatora transmembranske provodljivosti cistične fibroze | |
| JP2007518738A5 (enExample) | ||
| JP2014511892A5 (enExample) | ||
| ES2293530T3 (es) | Derivados de sulfonamidas para el tratamiento de enfermedades. | |
| RU2007109207A (ru) | Соединения-модуляторы активности рецептора сфингозин-1-фосфата (варианты), фармацевтическая композиция, содержащая указанные соединения, и способ лечения нарушения, ассоциированного со сфингозин-1-фосфатом | |
| JP2012524111A5 (enExample) | ||
| RU2014115290A (ru) | Производные 1-фенил 2-пиридинилалкиловых спиртов в качестве ингибиторов | |
| JP2010511626A5 (enExample) | ||
| JP2007531740A5 (enExample) | ||
| RU2012153164A (ru) | Производные мочевины и их терапевтическое применение при лечении, среди прочего, заболеваний дыхательного пути | |
| JP2020500182A5 (enExample) | ||
| JP2015501833A5 (enExample) | ||
| JP2019529490A5 (enExample) | ||
| JP2020510015A5 (enExample) | ||
| RU2014121090A (ru) | Модуляторы рецептора нмда и их применение | |
| JP2014517017A5 (ja) | 化合物、その医薬組成物、及び癌治療用の阻害薬としてのその使用 | |
| JP2009518296A5 (enExample) | ||
| JP2007505931A5 (enExample) | ||
| RU2006129312A (ru) | Производные ариланилина в качестве агонистов 2 адренергического рецептора | |
| JP2016501250A5 (enExample) |